Truist raised the firm’s price target on Covista (CVSA) to $140 from $130 and keeps a Buy rating on the shares after its Q3 earnings beat. The firm is citing the company having returned the Chamberlain segment to y/y enrollment growth a quarter early.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVSA:
- Adtalem Global Education Lifts Guidance on Solid Q3
- Covista reports Q3 adjusted EPS $1.98, consensus $1.72
- Covista raises FY26 adjusted EPS view to $7.95-$8.15 from $7.80-$8.00
- ATGE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Covista medical schools achieve 97% first-time residency attainment rate